National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)
Loading...
References
- Andrew D Zelenetz. NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.. Journal of the National Comprehensive Cancer Network : JNCCN, 2025
- T A Eyre. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.. Annals of oncology : official journal of the European Society for Medical Oncology, 2025
- J J Eertink. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.. Blood, 2023
- J. Jelicic. Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models. Blood Cancer Journal, 2023
- A. Ruppert. International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI.. Blood, 2020
- N. Schmitz. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016
- H. Adams. CT-based versus FDG-PET/CT-based NCCN international prognostic index risk stratification in DLBCL.. Journal of the National Comprehensive Cancer Network : JNCCN, 2015
- T. El‐Galaly. Outcome prediction by extranodal involvement, IPI, R‐IPI, and NCCN‐IPI in the PET/CT and rituximab era: A Danish–Canadian study of 443 patients with diffuse‐large B‐cell lymphoma. American Journal of Hematology, 2015
- Zheng Zhou. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.. Blood, 2014